drugset / Trial / NCT01193140

To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors

NCT01193140

Phase 2 Completed 24 enrolled Abbott
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerability of the veliparib/TMZ combination in subjects with solid tumors.

Timeline

Start
2010-07
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule Oral
Subject Veliparib Small molecule Oral

Indications

No indication recorded.